Covered recipient · General Payments record
DEBORAH M LONGWILL
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$5,980.48
- Reported across 143 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $368.20 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $221.90 | 11 |
| E.R. Squibb & Sons, L.L.C. | $66.25 | 2 |
| ORGANOGENESIS INC. | $25.48 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $24.30 | 1 |
| Verrica Pharmaceuticals Inc. | $23.61 | 1 |
| Biofrontera Inc. | $6.66 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $5.80 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899479 | CMS |
| ABBVIE INC. | $6.11 | 05/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899481 | CMS |
| ABBVIE INC. | $18.00 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899483 | CMS |
| ABBVIE INC. | $3.54 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899485 | CMS |
| ABBVIE INC. | $8.73 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899487 | CMS |
| ABBVIE INC. | $17.55 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899489 | CMS |
| ABBVIE INC. | $117.65 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899491 | CMS |
| ABBVIE INC. | $5.78 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899493 | CMS |
| ABBVIE INC. | $6.15 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899495 | CMS |
| ABBVIE INC. | $6.38 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899497 | CMS |
| ABBVIE INC. | $26.21 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899499 | CMS |
| Biofrontera Inc. | $6.66 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093026089 | CMS |
| E.R. Squibb & Sons, L.L.C. | $33.57 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101373104 | CMS |
| E.R. Squibb & Sons, L.L.C. | $32.68 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101373136 | CMS |
| Novartis Pharmaceuticals Corporation | $24.30 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087149048 | CMS |
| Organogenesis Inc. | $25.48 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145436847 | CMS |
| Verrica Pharmaceuticals Inc. | $23.61 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118383512 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.